|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics.
|
31794265 |
2020 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic variants in cytochrome P450 (CYP) (CYP2D6), dopamine receptor (DRD2, DRD3) and serotonin receptor (HTR2A, HTR2C) genes were previously associated with antipsychotic-induced hyperprolactinaemia.
|
31520576 |
2020 |
|
Hyperprolactinemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, due to competition for pituitary DRD2s by high dopamine levels may limit antipsychotic-induced HPRL.
|
30967134 |
2019 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Selfheal extract treated hyperprolactinemia through dopamine D2 receptor with significant effect.
|
28946556 |
2017 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
DRD2 Taq1A A2A2 polymorphisms may play a significant role in the hyperprolactinemia- associated with risperidone treatment in children and adolescent with autism spectrum disorder.
|
26872113 |
2016 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the frequency of hyperprolactinemia in children and adolescents treated with risperidone, and its associations with clinical and pharmacological data and certain polymorphisms of the following genes: Dopamine receptor D2 (DRD2), 5-hydroxytryptamine (serotonin) receptor 2C (HTR2C), cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), leptin (LEP), leptin receptor (LEPR), melanocortin 4 receptor (MC4R), and scavenger receptor class B, member 2 (SCARB2).
|
26682995 |
2015 |
|
Hyperprolactinemia
|
0.600 |
Therapeutic
|
disease |
RGD |
Studies on the regulatory effect of Peony-Glycyrrhiza Decoction on prolactin hyperactivity and underlying mechanism in hyperprolactinemia rat model.
|
26297122 |
2015 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Data suggests that dopamine receptor DRD2 gene variants may contribute to hyperprolactinemia and that they may be risk factors for endometriosis-related infertility.
|
25955176 |
2015 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although CYP2D6 might have an effect, the presence of at least one Taq1A A1 allele of the D2DR gene did not contribute toward susceptibility to risperidone-induced hyperprolactinemia, and as a result, toward prolactin-related adverse events such as amenorrhea, galactorrhea, and sexual dysfunctioning.
|
23851570 |
2013 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.
|
19896213 |
2010 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
CTD_human |
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
|
19339912 |
2009 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The effect of the TaqIA variants of the DRD2 on the risk of risperidone-induced hyperprolactinemia was the primary outcome measure.
|
19339912 |
2009 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analysis of the DRD2 genotypes demonstrates an odds ratio of 6.77 (2.39, 19.14; 95% confidence interval) for the polymorphism 1 homozygous state in hyperprolactinemia.
|
16169407 |
2005 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
CTD_human |
Hyperprolactinaemia induced by D(2) dopamine receptor antagonist antipsychotic medication can result in significant health problems.
|
15286066 |
2004 |